PEN — Penumbra Inc
—
NYSE ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1321732 ·
Last close
$318.73
Market Cap
$12.54B
52W High
$331.80
52W Low
$314.80
ADV30
401,446
Next earnings
2026-07-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 374,758,000 | 253,411,000 | 38,234,000 | 32,584,000 | 1,898,438,000 | 241,289,000 | 424,626,000 |
| Dec 2025 | 385,385,000 | 262,128,000 | 59,233,000 | 47,343,000 | 1,826,519,000 | 186,897,000 | 398,916,000 |
| Sep 2025 | 354,685,000 | 240,416,000 | 48,838,000 | 45,851,000 | 1,744,369,000 | 321,029,000 | 385,673,000 |
| Jun 2025 | 339,455,000 | 224,010,000 | 40,828,000 | 45,270,000 | 1,674,809,000 | 421,768,000 | 380,858,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$276,664,000
Investing CF
$-434,721,000
Financing CF
$21,917,000
CapEx
$-63,933,000
Dividends Paid
—
Buybacks
$1,000
EPS Diluted TTM
$4.34
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$270,275,000
Inventory
$438,539,000
Receivables
$183,295,000
ST Investments
$374,371,000
EBIT TTM
$204,262,000
Pretax Income TTM
$202,955,000
Interest Exp TTM
$1,307,000
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,454,283,008
EBITDA
$203,963,008
Free Cash Flow
$141,799,872
Enterprise Value
$12,103,974,912
Total Cash
$615,660,032
Total Debt
$216,175,008
Shares Out
39,331,425
Trailing EPS
$4.36
Book Value
$37.48
ROE
12.7%
ROA
6.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,403,665,000 | 189,249,000 | 177,687,000 | 1,826,519,000 | 398,916,000 | — | 238,663,000 |
| Dec 2024 | 1,194,615,000 | 86,224,000 | 14,012,000 | 1,533,181,000 | 382,250,000 | — | 168,481,000 |
| Dec 2023 | 1,058,522,000 | 91,766,000 | 90,954,000 | 1,556,305,000 | 377,361,000 | — | 97,333,000 |
| Dec 2022 | 847,133,000 | 6,082,000 | -2,002,000 | 1,370,886,000 | 372,028,000 | — | -55,661,000 |
TTM Snapshot
Revenues TTM
$975,780,000
NetIncome TTM
$45,320,000
OpCashFlow TTM
$0
Assets (Latest)
$1,533,181,000
Forward EPS
$6.25
Max Pain — expiry 2027-01-15
max pain strike: $380.00 · spot: $318.73 · call oi: 1,601 · put oi: 3,502
Expected Move to 2027-01-15:
±$140.00
(43.92%) —
implied range
$178.73 –
$458.73
· ATM straddle on $320.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SNNUF | SMITH & NEPHEW PLC | $12.71B | $15.10 | — |
| SNN | SMITH & NEPHEW PLC | $12.86B | $30.57 | — |
| ALGN | ALIGN TECHNOLOGY INC | $11.96B | $167.01 | — |
| SOLV | Solventum Corp | $13.51B | $78.01 | — |
| BAX | BAXTER INTERNATIONAL INC | $11.57B | $22.40 | — |
News headlines (Yahoo Finance, 1h cache)
Magnendo Secures $18M Series A Financing to Transform Endovascular Access for Stroke Intervention
2026-07-24 12:30 · Yahoo
THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care
2026-07-22 18:35 · Yahoo
3 Medical Device Stocks Giving Investors a Different Healthcare Play
2026-07-20 13:40 · Yahoo
IQV vs. PEN: Which Stock Is the Better Value Option?
2026-07-14 15:40 · Yahoo
First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
2026-07-07 13:00 · Yahoo
GuideAI Health Appoints Renowned Interventional Radiologist Dr. James Benenati to Advisory Board Following FDA 510(k) Clearance of VAOT
2026-07-06 12:00 · Yahoo
GMED vs. PEN: Which Stock Should Value Investors Buy Now?
2026-06-22 15:40 · Yahoo
Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?
2026-06-18 16:47 · Yahoo
ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains?
2026-06-18 10:36 · Yahoo
Penumbra wins CE mark for Thunderbolt clot removal tech
2026-06-18 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.